Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ovarian Cycle01:27

Ovarian Cycle

2.0K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
2.0K
Proliferative Phase01:20

Proliferative Phase

873
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
873
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

46
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
46
Secretory Phase01:19

Secretory Phase

1.4K
The secretory phase of the menstrual cycle, spanning from day 14 to 28 in a typical 28-day cycle, is a period of significant physiological changes in the female reproductive system. This phase commences immediately after ovulation and is characterized by the preparation of the endometrium for potential embryo implantation.
Following ovulation, the corpus luteum, a temporary endocrine structure, produces progesterone and estrogens. These hormones stimulate the growth and coiling of endometrial...
1.4K
Teratogenicity01:07

Teratogenicity

2.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.9K
Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

1.9K
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

U.S. study of Scandinavian prison model expands.

Science (New York, N.Y.)·2025
Same author

Psychedelic trials face downsides of the 'trip'.

Science (New York, N.Y.)·2025
Same author

A new 'mini-CRISPR' flexes its editing power in monkey muscles.

Science (New York, N.Y.)·2025
Same author

Runners-up.

Science (New York, N.Y.)·2024
Same author

Storm warnings for FDA and CDC.

Science (New York, N.Y.)·2024
Same author

Preprint on Alzheimer's drug deaths ignites author dispute.

Science (New York, N.Y.)·2024
Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026
Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026
Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026
Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026
Same journal

Retraction.

Science (New York, N.Y.)·2026
Same journal

Making time.

Science (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Sep 30, 2025

Anogenital Distance and Perineal Measurements of the Pelvic Organ Prolapse POP Quantification System
03:49

Anogenital Distance and Perineal Measurements of the Pelvic Organ Prolapse POP Quantification System

Published on: September 20, 2018

19.6K

The pregnancy gap.

Jennifer Couzin-Frankel

    Science (New York, N.Y.)
    |March 17, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Limited data exists on medication safety during pregnancy. There is a growing need to improve evidence generation for pregnant individuals and their developing fetuses.

    More Related Videos

    Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination
    05:36

    Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination

    Published on: July 7, 2023

    8.7K
    Is My Mouse Pregnant? High-Frequency Ultrasound Assessment
    02:39

    Is My Mouse Pregnant? High-Frequency Ultrasound Assessment

    Published on: March 18, 2021

    7.5K

    Related Experiment Videos

    Last Updated: Sep 30, 2025

    Anogenital Distance and Perineal Measurements of the Pelvic Organ Prolapse POP Quantification System
    03:49

    Anogenital Distance and Perineal Measurements of the Pelvic Organ Prolapse POP Quantification System

    Published on: September 20, 2018

    19.6K
    Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination
    05:36

    Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination

    Published on: July 7, 2023

    8.7K
    Is My Mouse Pregnant? High-Frequency Ultrasound Assessment
    02:39

    Is My Mouse Pregnant? High-Frequency Ultrasound Assessment

    Published on: March 18, 2021

    7.5K

    Area of Science:

    • Pharmacology
    • Reproductive Health
    • Clinical Research

    Background:

    • Drug safety data in pregnant populations is significantly lacking.
    • This evidence gap poses risks to both maternal and fetal health.
    • Current regulatory and research practices are insufficient.

    Discussion:

    • The scarcity of drug safety information during pregnancy necessitates a paradigm shift.
    • Ethical and logistical challenges hinder robust clinical trials in pregnant individuals.
    • Existing observational data often lacks the detail needed for definitive safety conclusions.

    Key Insights:

    • There is an urgent call to enhance the evidence base for medication use in pregnancy.
    • Improved data collection and research methodologies are critical.
    • Addressing this gap is essential for informed clinical decision-making.

    Outlook:

    • Future research should prioritize generating high-quality safety data for drugs used by pregnant women.
    • Policy changes are needed to encourage and facilitate drug safety studies in pregnancy.
    • A collaborative effort is required to overcome existing barriers and improve outcomes.